Proteomic biomarkers for the prediction of transition to psychosis in individuals at clinical high risk: A multi-cohort model development study

Byrne, Jonah F., Healy, Colm, Föcking, Melanie, Susai, Subash Raj, Mongan, David, Wynne, Kieran, Kodosaki, Eleftheria, Heurich-Sevcenco, Meike ORCID: https://orcid.org/0000-0003-0105-2702, de Haan, Lieuwe, Hickie, Ian B, Smesny, Stefan, Thompson, Andrew, Markulev, Connie, Young, Alison Ruth, Schäfer, Miriam R, Riecher-Rössler, Anita, Mossaheb, Nilufar, Berger, Gregor, Schlögelhofer, Monika, Nordentoft, Merete, Chen, Eric Y H, Verma, Swapna, Nieman, Dorien H, Woods, Scott W, Cornblatt, Barbara A, Stone, William S, Mathalon, Daniel H, Bearden, Carrie E, Cadenhead, Kristin S, Addington, Jean, Walker, Elaine F, Cannon, Tyrone D, Cannon, Mary, McGorry, Pat, Amminger, Paul, Cagney, Gerard, Nelson, Barnaby, Jeffries, Clark, Perkins, Diana and Cotter, David R 2024. Proteomic biomarkers for the prediction of transition to psychosis in individuals at clinical high risk: A multi-cohort model development study. Schizophrenia Bulletin 10.1093/schbul/sbad184

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (263kB) | Preview

Abstract

Psychosis risk prediction is one of the leading challenges in psychiatry. Previous investigations have suggested that plasma proteomic data may be useful in accurately predicting transition to psychosis in individuals at clinical high risk (CHR). We hypothesized that an a priori-specified proteomic prediction model would have strong predictive accuracy for psychosis risk and aimed to replicate longitudinal associations between plasma proteins and transition to psychosis. This study used plasma samples from participants in 3 CHR cohorts: the North American Prodrome Longitudinal Studies 2 and 3, and the NEURAPRO randomized control trial (total n = 754). Plasma proteomic data were quantified using mass spectrometry. The primary outcome was transition to psychosis over the study follow-up period. Logistic regression models were internally validated, and optimism-corrected performance metrics derived with a bootstrap procedure. In the overall sample of CHR participants (age: 18.5, SD: 3.9; 51.9% male), 20.4% (n = 154) developed psychosis within 4.4 years. The a priori-specified model showed poor risk-prediction accuracy for the development of psychosis (C-statistic: 0.51 [95% CI: 0.50, 0.59], calibration slope: 0.45). At a group level, Complement C8B, C4B, C5, and leucine-rich α-2 glycoprotein 1 (LRG1) were associated with transition to psychosis but did not surpass correction for multiple comparisons. This study did not confirm the findings from a previous proteomic prediction model of transition from CHR to psychosis. Certain complement proteins may be weakly associated with transition at a group level. Previous findings, derived from small samples, should be interpreted with caution.

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Pharmacy
Publisher:	Oxford University Press
ISSN:	0586-7614
Date of First Compliant Deposit:	19 April 2024
Date of Acceptance:	19 January 2024
Last Modified:	19 Apr 2024 13:03
URI:	https://orca.cardiff.ac.uk/id/eprint/168160

Actions (repository staff only)

Edit Item